Leticia Monin

Leticia Monin

Auto-generated profile, based on publicly available information

Leticia Monin

The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAdam G. Laing
Adam G. Laing
ALAnna Lorenc
Anna Lorenc
IBIrene del Molino del Barrio
Irene del Molino del Barrio
ADAbhishek Das
Abhishek Das
MFMatthew Fish
Matthew Fish
AHAdrian C. Hayday
Adrian C. Hayday

28 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AJAnett Jandke
Anett Jandke
DMDaisy Melandri
Daisy Melandri
LMLeticia Monin
Leticia Monin
DUDmitry S Ushakov
Dmitry S Ushakov
ALAdam G. Laing
Adam G. Laing
AHAdrian Hayday
Adrian Hayday
Butyrophilin-like (Btnl) genes are emerging as major epithelial determinants of tissue-associated γδ T cell compartments. Thus, the development of signature, murine TCRγδ+ intraepithelial lymphocytes (IEL) in gut and skin depends on Btnl family members, Btnl1 and Skint1, respectively. In seeking mechanisms underlying these profound effects, we now show that normal gut and skin γδ IEL development additionally requires Btnl6 and Skint2, respectively, and furthermore that different Btnl heteromers can seemingly shape different intestinal γδ+ IEL repertoires. This formal genetic evidence for the importance of Btnl heteromers also applied to the steady-state, since sustained Btnl expression is required to maintain the signature TCR.Vγ7+ IEL phenotype, including specific responsiveness to Btnl proteins. In sum, Btnl proteins are required to select and to maintain the phenotypes of tissue-protective γδ IEL compartments, with combinatorially diverse heteromers having differential impacts on different IEL subsets.

1 January 2013 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
EBEdgardo Berriel
Edgardo Berriel
SRSofía Russo
Sofía Russo
LMLeticia Monin
Leticia Monin
MFMaría Florencia Festari
María Florencia Festari
NBNora Berois
Nora Berois
EOEduardo Osinaga
Eduardo Osinaga
This study evaluates the antitumor immune response induced by human hydatic cyst fluid (HCF) in an animal model of colon carcinoma. We found that anti‐HCF antibodies were able to identify cell surface and intracellular antigens in CT26 colon cancer cells. In prophylactic tumor challenge experiments, HCF vaccination was found to be protective against tumor formation for 40% of the mice (P = 0.01). In the therapeutic setting, HCF vaccination induced tumor regression in 40% of vaccinated mice (P = 0.05). This vaccination generated memory immune responses that protected surviving mice from tumor rechallenge, implicating the development of an adaptive immune response in this process. We performed a proteomic analysis of CT26 antigens recognized by anti‐HCF antibodies to analyze the immune cross‐reactivity between E. granulosus (HCF) and CT26 colon cancer cells. We identified two proteins: mortalin and creatine kinase M‐type. Interestingly, CT26 mortalin displays 60% homology with E. granulosus hsp70. In conclusion, our data demonstrate the capacity of HCF vaccination to induce antitumor immunity which protects from tumor growth in an animal model. This new antitumor strategy could open new horizons in the development of highly immunogenic anticancer vaccines.

29 May 2020 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
LML. Monin
L. Monin
DUD. S. Ushakov
D. S. Ushakov
HAH. Arnesen
H. Arnesen
NBN. Bah
N. Bah
AJA. Jandke
A. Jandke
AHA. Hayday
A. Hayday
This most comprehensive analysis to date of γδ T cells in the murine uterus reveals them to compose a unique local T-cell compartment. Consistent with earlier reports, most cells expressed a canonical Vγ6Vδ1 TCR, and produced interleukin (IL)-17A upon stimulation. Nonetheless, contrasting with earlier reports, uterine γδ T cells were not obviously intraepithelial, being more akin to sub-epithelial Vγ6Vδ1+ T cells at several other anatomical sites. By contrast to other tissues however, the uterine compartment also included non-Vγ6+, IFN-γ-producing cells; was strikingly enriched in young mice; expressed genes hitherto associated with the uterus, including the progesterone receptor; and did not require microbes for development and/or maintenance. This notwithstanding, γδ T-cell deficiency severely impaired resistance to reproductive tract infection by Candida albicans, associated with decreased responses of IL-17-dependent neutrophils. These findings emphasise tissue-specific complexities of different mucosal γδ cell compartments, and their evident importance in lymphoid stress-surveillance against barrier infection.

27 November 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAdam G. Laing
Adam G. Laing
ALAnna Lorenc
Anna Lorenc
IBIrene del Molino del Barrio
Irene del Molino del Barrio
ADAbhishek Das
Abhishek Das
MFMatthew Fish
Matthew Fish
AHAdrian C. Hayday
Adrian C. Hayday

17 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
LMLeticia Monin-Aldama
Leticia Monin-Aldama
ALAdam G. Laing
Adam G. Laing
MMMiguel Muñoz-Ruiz
Miguel Muñoz-Ruiz
DMDuncan R McKenzie
Duncan R McKenzie
IBIrene del Molino del Barrio
Irene del Molino del Barrio
SISheeba Irshad
Sheeba Irshad
Background The efficacy and safety profile of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in immunocompromised patient populations. Patients with a known cancer diagnosis were hitherto excluded from trials of the vaccines currently in clinical use. Methods This study presents data on the safety and immune efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malignancies, respectively, and compares results for patients who were boosted with BNT162b2 at 3 weeks versus those who were not. Immune efficacy was measured as antibody seroconversion, T cell responses, and neutralisation of SARS-CoV-2 Wuhan strain and of a variant of concern (VOC) (B.1.1.7). We also collected safety data for the BNT162b2 vaccine up to 5 weeks following first dose. Findings The vaccine was largely well tolerated. However, in contrast to its very high performance in healthy controls (>90% efficacious), immune efficacy of a single inoculum in solid cancer patients was strikingly low (below 40%) and very low in haematological cancer patients (below 15%). Of note, efficacy in solid cancer patients was greatly and rapidly increased by boosting at 21-days (95% within 2 weeks of boost). Too few haematological cancer patients were boosted for clear conclusions to be drawn. Conclusions Delayed boosting potentially leaves most solid and haematological cancer patients wholly or partially unprotected, with implications for their own health; their environment and the evolution of VOC strains. Prompt boosting of solid cancer patients quickly overcomes the poor efficacy of the primary inoculum in solid cancer patients. Evidence before this study Some cancer patients have been shown to exhibit sustained immune dysregulation, inefficient seroconversion and prolonged viral shedding as a consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Consequently, their exclusion and, in particular, the exclusion of patients receiving systemic anti-cancer therapies, from the registry trials of the 5 approved COVID-19 vaccines raises questions about the efficacy and safety of SARS-CoV-2 vaccination in this patient population. In addition, whilst the change in the UK’s dosing interval to 12-weeks aimed to maximise population coverage, it is unclear whether this strategy is appropriate for cancer patients and those on systemic anti-cancer therapies. Added value of this study We report that the RNA-based SARS-CoV-2 BNT162b2 vaccine administered in cancer patients was well tolerated, and we provide first insights into both antibody and T cell responses to the vaccine in an immunocompromised patient population. Implications of all the available evidence In cancer patients, one dose of 30ug of BNT162b2 yields poor vaccine efficacy, as measured by seroconversion rates, viral neutralisation capacity and T cell responses, at 3- and 5-weeks following the first inoculum. Patients with solid cancers exhibited a significantly greater response following a booster at 21-days. These data support prioritisation of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine. Given the globally poor responses to vaccination in patients with haematological cancers, post-vaccination serological testing, creation of herd immunity around these patients using a strategy of ‘ring vaccination’, and careful follow-up should be prioritised.